
Mycronic AB
Mycronic
Mycronic may be smaller than its Japanese and American rivals, but the Swedish specialist holds near-monopoly positions in two niches that matter enormously to advanced electronics manufacturers. In 2025 the company delivered net sales of SEK 7.938 billion (about USD 750 million), up 12%, with an EBIT margin of 24% — among the highest in the equipment industry — and set a record quarterly operating profit in Q1 2026, prompting management to raise its 2026 guidance to SEK 8.75 billion. With 2,673 employees and operations in nearly 50 countries, Mycronic dominates solder paste jet printing (a stencil-free technology essential for aerospace, medical, and defense boards) and the high-mix/low-volume placement segment.
Strengths: The MYPro series flexible mounters and jet printers command premium pricing in high-mix/low-volume production, where changeover speed matters more than raw CPH. The jet printing monopoly position — no stencil required — makes Mycronic effectively indispensable for complex, high-reliability boards in aerospace, medical, and military applications. The 2025 acquisition of German test-probe maker ETZ extends its PCB test portfolio, while the GenI system applies generative AI to AOI programming, a breakthrough that could reshape inspection workflows. The new Thailand factory diversifies production away from single-region risk.
Weaknesses: Management indefinitely shelved the IPO of its Axxon subsidiary on the Chinese stock exchange, citing the depressed Chinese capital market and limiting access to local funding. The China market remains soft, weighing on the High Volume segment. With its reliance on specialized niches, Mycronic's growth is tied to the fortunes of high-mix electronics manufacturers, which are more sensitive to economic cycles than high-volume consumer lines.Read MoreShow Less
Strengths: The MYPro series flexible mounters and jet printers command premium pricing in high-mix/low-volume production, where changeover speed matters more than raw CPH. The jet printing monopoly position — no stencil required — makes Mycronic effectively indispensable for complex, high-reliability boards in aerospace, medical, and military applications. The 2025 acquisition of German test-probe maker ETZ extends its PCB test portfolio, while the GenI system applies generative AI to AOI programming, a breakthrough that could reshape inspection workflows. The new Thailand factory diversifies production away from single-region risk.
Weaknesses: Management indefinitely shelved the IPO of its Axxon subsidiary on the Chinese stock exchange, citing the depressed Chinese capital market and limiting access to local funding. The China market remains soft, weighing on the High Volume segment. With its reliance on specialized niches, Mycronic's growth is tied to the fortunes of high-mix electronics manufacturers, which are more sensitive to economic cycles than high-volume consumer lines.
Listed market data
MYCR · STO · weeklyHistory →- Market cap
- $6.1 B
- Share price
- SEK 301.60
- 1Y change
- +33.8%
- Recent change
- +1.5%
- Since first close
- +129.8%
- Revenue (TTM)
- $950 M
11-18 → 11-19
from 2000
Financial history
Full market history- 2026-11SEK 301.60$6.1 B+1.1%
- 2026-10SEK 298.20$5.7 B0.0%
- 2026-09SEK 298.20$5.7 B-11.8%
- 2026-08SEK 338.20$6.4 B+3.8%
- 2026-07SEK 325.80$6.2 B+3.8%
- 2026-06SEK 313.80$6 B-2.3%
- 2026-05SEK 321.20$6.1 B+7.8%
- 2026-04SEK 298.00$5.7 B+3.1%
- 2026-03SEK 289.00$5.5 B+32.6%
- 2026-02SEK 218.00$4.2 B+6.2%
- 2026-01SEK 205.30$3.9 B-0.2%
- 2025-12SEK 205.80$3.9 B—
Ownership & Control
Latest available filings- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Brand & Manufacturer
- Insiders
- 0.20%
- Institutions
- 79.11%(158 holders)
- Free float
- 79.27%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines1- Mycronic Receives Order For An Slx Mask Writer - TradingViewwww.tradingview.com2026-10-20
- Mycronic receives order for an SLX mask writer - TradingViewwww.tradingview.com2026-10-20
- Mycronic AB (publ) (MYCR) Books $5–7M SLX Mask Writer Order - TradingViewwww.tradingview.com2026-10-20
- Mycronic (OM:MYCR) Wins A US Mask Writer Order, Is The Stock Still Undervalued? - Simply Wall Streetsimplywall.st2026-10-20
- Handelsbanken: Mycronic remains a buy despite share price gains - www.marketscreener.comwww.marketscreener.com2026-10-14
• MYPro series flexible placement machines for high-mix/low-volume production
• MY series solder paste jet printers stencil-free, for complex and high-reliability boards
• Dispensing equipment for underfill, conformal coating, and bonding applications
• PCB test systems following the ETZ acquisition
High Volume Dispensing - Core Business
• Axxon high-speed jet dispensing systems for consumer electronics and automotive
Other Technologies - Core Business
• Mask writers and photomask manufacturing equipment for display and semiconductor industries
• GenI generative-AI AOI programming systemBare Board Testing – Core Business
• atg Mycronic flying-probe testers for HDI and rigid-flex boards
• Universal grid test systems for high-reliability server and aerospace PCBs
• A9XL platform for ultra-large backplanes and supercomputer boards
Quick Facts
Headquarters
Founded
Employees
Revenue
Market cap
Factories
Presence
Categories
19 categories · scroll for more
Related
Similar listed companies
- Nvidia Corporation· $3.1 T
- Samsung Electronics Co., Ltd.· $955 B
- Micron Technology, Inc.· $953 B
- ASML Holding N.V.· $598 B
- Cisco· $497 B
- Arista Networks· $439 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website Nasdaq Stockholm: MYCR , Mycronic Year-end Report 2025 (official)
Mycronic Record Q1 2026 (I-Connect007)
Mycronic Official Website
